No Data
Guizhou Yibai Pharmaceutical Co., Ltd. 2024 Annual Results Forecast
Guizhou Yibai Pharmaceutical (600594.SH): Expected loss of 0.285 billion yuan to 0.342 billion yuan in 2024.
Gelonghui reported on January 17 that Guizhou Yibai Pharmaceutical (600594.SH) announced its annual performance forecast for 2024, expecting a net income attributable to the parent company's owners to be between -342 million yuan and -285 million yuan; this represents a loss compared to the same period last year. The company expects a net income attributable to the parent company's owners, excluding non-recurring gains and losses, to be between -348 million yuan and -290 million yuan for 2024.
Shareholders in Guizhou Yibai Pharmaceutical (SHSE:600594) Have Lost 57%, as Stock Drops 16% This Past Week
Guizhou Yibai Pharmaceutical (600594.SH): has actually repurchased 0.95% of the company's shares.
On November 28, 2023, Guizhou Yibai Pharmaceutical (600594.SH) announced that the deadline for the share repurchase has expired. The company has completed the repurchase, having repurchased a total of 7,533,500 shares through centralized bidding. The repurchased shares account for 0.95% of the company's total share capital, with the highest transaction price being 4.10 yuan per share, the lowest price being 2.89 yuan per share, and the average repurchase price being 3.32 yuan per share. The total amount paid is 24,991,703 yuan (excluding transaction commissions and other transaction costs).
Guizhou Yibai Pharmaceutical (600594.SH): Currently, the company's focus on health products is mainly on throat lozenges, instant beverages, and solid beverages.
Gelonghui November 11th | Guizhou Yibai Pharmaceutical (600594.SH) expressed on the investor interaction platform that the company currently has anti-tumor products such as injection L-OHP, Kangsaidi capsules, and Aiyu capsules. Currently, the company's health products are mainly focused on throat lozenges, instant drinks, solid beverages, etc.
Guizhou Yibai Pharmaceutical (600594.SH): The company did not repurchase in October.
On November 1st, Guizhou Yibai Pharmaceutical (600594.SH) announced that in October 2024, the company did not repurchase any shares. As of the end of October 2024, the company has repurchased a total of 5,037,400 shares through centralized competitive trading, accounting for 0.64% of the total share capital. The highest repurchase price was 3.06 yuan per share, the lowest price was 2.89 yuan per share, and the total amount paid was RMB 14,997,308 (excluding transaction fees such as trading commissions).
The Market Doesn't Like What It Sees From Guizhou Yibai Pharmaceutical Co., Ltd.'s (SHSE:600594) Revenues Yet As Shares Tumble 25%